Publisher
Springer International Publishing
Reference113 articles.
1. Fishbein L, Nathanson KL. Pheochromocytoma and paraganglioma: understanding the complexities of the genetic background. Cancer Genet. 2012;205(1–2):1–11.
2. Gupta G, Pacak K, AACE Adrenal Scientific Committee. Precision medicine: an update on genotype- biochemical phenotype relationships in Pheochromocytoma/Paraganglioma patients. Endoc Pract Off J Am Coll Endocrinol Am Assoc Clin Endocrinologists. 2017;23:690–704.
3. Lenders JW, Eisenhofer G, Mannelli M, Pacak K. Phaeochromocytoma. Lancet. 2005;366(9486):665–75.
4. Ayala-Ramirez M, Feng L, Johnson MM, Ejaz S, Habra MA, Rich T, et al. Clinical risk factors for malignancy and overall survival in patients with pheochromocytomas and sympathetic paragangliomas: primary tumor size and primary tumor location as prognostic indicators. J Clin Endocrinol Metab. 2011;96(3):717–25.
5. Hescot S, Leboulleux S, Amar L, Vezzosi D, Borget I, Bournaud-Salinas C, et al. One- year progression-free survival of therapy-naive patients with malignant pheochromocytoma and paraganglioma. J Clin Endocrinol Metab. 2013;98(10):4006–12.